{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer&page=4&q=gastroesophageal+junction", "query": { "q": "gastroesophageal junction", "condition": "Gastric Cancer", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 339, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer&page=5&q=gastroesophageal+junction&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer&page=3&q=gastroesophageal+junction&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T12:39:18.616Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04069273", "title": "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "GastroEsophageal Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab Monotherapy", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harry H Yoon", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-12-01", "completion_date": "2027-12-10", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Milwaukee, Wisconsin", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04069273" }, { "nct_id": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "INCAGN01949", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2017-10-09", "completion_date": "2019-09-17", "has_results": true, "last_update_posted_date": "2022-09-27", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03241173" }, { "nct_id": "NCT03641313", "title": "Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Berzosertib", "type": "DRUG" }, { "name": "Computed Tomography Assisted Biopsy", "type": "PROCEDURE" }, { "name": "Endoscopic Biopsy", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-11-16", "completion_date": "2027-01-28", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 31, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03641313" }, { "nct_id": "NCT01928290", "title": "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stomach Neoplasms", "Esophageal Neoplasms" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2013-11-08", "completion_date": "2019-10-28", "has_results": true, "last_update_posted_date": "2020-08-25", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01928290" }, { "nct_id": "NCT01178944", "title": "Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Undifferentiated Carcinoma", "Gastric Adenocarcinoma", "Gastric Squamous Cell Carcinoma", "Recurrent Esophageal Adenocarcinoma", "Recurrent Esophageal Squamous Cell Carcinoma", "Recurrent Gastric Carcinoma", "Stage IIIB Esophageal Adenocarcinoma", "Stage IIIB Esophageal Squamous Cell Carcinoma", "Stage IIIB Gastric Cancer", "Stage IIIC Esophageal Adenocarcinoma", "Stage IIIC Esophageal Squamous Cell Carcinoma", "Stage IIIC Gastric Cancer", "Stage IV Esophageal Adenocarcinoma", "Stage IV Esophageal Squamous Cell Carcinoma", "Stage IV Gastric Cancer", "Undifferentiated Gastric Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2010-09", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-12-13", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 2, "location_summary": "Buffalo, New York • Rochester, New York", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01178944" }, { "nct_id": "NCT03615326", "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Neoplasms", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2018-10-05", "completion_date": "2025-11-12", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 23, "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03615326" }, { "nct_id": "NCT01939275", "title": "64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Recurrent Gastric Cancer", "Stage IA Gastric Cancer", "Stage IB Gastric Cancer", "Stage IIA Gastric Cancer", "Stage IIB Gastric Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Gastric Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "copper Cu 64-DOTA-trastuzumab", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "DEVICE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DEVICE", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-11-19", "completion_date": "2024-08-05", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01939275" }, { "nct_id": "NCT04161781", "title": "A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophagogastric Cancer", "Esophagus Cancer", "Esophageal Cancer", "Gastric Cancer", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Gastroesophageal Junction Squamous Cell Carcinoma" ], "interventions": [ { "name": "18F-BMS-986229 Injection", "type": "DRUG" }, { "name": "IV 18F-BMS-986229", "type": "DRUG" }, { "name": "PET/CT Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-11-12", "completion_date": "2024-03-06", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04161781" }, { "nct_id": "NCT04931654", "title": "A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Gastric Cancer", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "AZD7789", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 136, "start_date": "2021-09-28", "completion_date": "2026-08-12", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04931654" }, { "nct_id": "NCT03511222", "title": "Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Vorolanib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2018-09-11", "completion_date": "2020-05-28", "has_results": false, "last_update_posted_date": "2020-07-29", "last_synced_at": "2026-10-14T12:39:18.616Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511222" } ] }